Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
AbstractThe Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1/p-STAT3 in cancers. Lastly, we will summarize and highlight work involving novel drugs/compounds targeting SHP-1/p-STAT3 signaling and combined strategies that were/are discovered in our and our colleagues’ laboratories. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Huang, T.-T.; Su, J.-C.; Liu, C.-Y.; Shiau, C.-W.; Chen, K.-F. Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. Int. J. Mol. Sci. 2017, 18, 1234.
Huang T-T, Su J-C, Liu C-Y, Shiau C-W, Chen K-F. Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. International Journal of Molecular Sciences. 2017; 18(6):1234.Chicago/Turabian Style
Huang, Tzu-Ting; Su, Jung-Chen; Liu, Chun-Yu; Shiau, Chung-Wai; Chen, Kuen-Feng. 2017. "Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy." Int. J. Mol. Sci. 18, no. 6: 1234.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.